Radiation Oncology

The Department of Radiation Oncology

The Radiation Oncology Department at the Canberra Region Cancer Centre provides comprehensive state-of-the-art radiotherapy services including external beam, HDR brachytherapy, superficial radiation treatments and LDR (seed implant) prostate brachytherapy treatment options.

Radiation therapy treatment involves initial consultation with a radiation oncology staff specialist, computerised tomography simulation for localisation of the region to be treated, treatment planning and delivery of the treatment course and progress checks.

Refer a patient

Patients must have a valid referral from their general practitioner or from another specialist.

The Canberra Region Cancer Centre at the Canberra Hospital is the main treatment location of the Department of Radiation Oncology.

Staff specialist outpatient clinics are conducted on Level 1 of the Canberra Region Cancer Centre and access to a wide range of multidisciplinary services is available.

Referrals can be faxed to: Radiation Oncology (02) 6244 2276.

Find a Specialist

The Radiation Oncology Department is committed to providing high-quality cancer management.

The team consists of highly skilled Radiation Oncologists, Radiation Therapists, Nurses, Physicists and other allied health professionals.

  • Associate Professor Hany Elsaleh, Clinical Director, Radiation Oncology
  • Sarah Mogford, Director of Radiation Therapy
  • Dr Brandon Nguyen, Radiation Oncologist
  • Dr Amy Shorthouse, Radiation Oncologist
  • Dr Lyn Austen, Radiation Oncologist
  • Dr Lisa Sullivan, Radiation Oncologist
  • Dr Angela Rezo, Radiation Oncologist
  • Dr Andrew Lee, Radiation Oncologist
  • Dr Yu-Yan Fang, Clinical Trial Coordinator
  • Michelle Nolan (RN), Clinical Trial Coordinator
  • Edward Craft, Clinical Trial Coordinator
  • Dr Trish Pulvirenti, Radiation Oncologist
  • Dr Isabel Lee, Radiation Oncologist

Clinical Trials

Radiation Oncology - national / international clinical trials

  • ctDNA in rectal cancer - Circulating Tumour DNA as a marker of complete pathological response and long term outcome for locally advanced rectal cancer treated with pro-operative chemo radiotherapy.
  • SCORAD III - A Randomised Phase III Trial of Single Fraction Radiotherapy Compared to Multi-Fraction Radiotherapy in Patients with metastic Spinal Cord Compression.
  • STARS - A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy.
  • CHISEL - A randomised phase III trial of highly conformal hypo fractionated image guided ("stereotactic") radiotherapy (HypoRT) versus conventionally fractionated radiotherapy (ConRT) for inoperable early stage I non-small cell lung cancer.
  • Aviator - AudioVisual Investigation Advancing Thoracic Radiotherapy.


The Radiation Oncology Department at the Canberra Region Cancer Centre is committed to continuous improvement in cancer treatment by advancing innovative technology and research.

Radiation Oncology aims to provide an environment where many staff are given opportunities to participate in research activities that ultimately will have a positive impact on patient care.

Considerable time and effort has been devoted by personnel within the department in obtaining technical credentialing and training of staff to support participation in Trans Tasman Radiation Oncology Cooperative Group (TROG) trials.

We also encourage local and interstate departmental collaborations with our ACT Health and Peter Mac colleagues, universities (eg: ANU, University of Sydney and Melbourne University) and clinical research trial groups (TROG).

Radiation Oncology is participating in international and clinical and translational trials such as ctDNA in rectal cancer, SCORAD III, and STARS.

Radiation Oncology trainees and fellows are actively involved in Clinical Research trials and projects at the department that enables them to gain research experience, and enhance their clinical training.

In addition Radiation Oncology supports the Cancer Research Laboratory (gastric cancer carcinogenesis) and participates in local translational research.

Further work is being done to expand laboratory-based research for the unit. The recent recruitment and support of a Radiation Biologist allows bridging clinical advances in cancer therapy with laboratory-based investigations.

The Department of Radiation Oncology have been long term contributors and supporters of the longitudinal Breast Cancer Treatment Group project as well as the Medical Oncology Trials Unit and the ANU Research Charm event.

Clinical and Laboratory Research Projects

  • ER stress in mucous metaplasia and gastric cancer (2011-2015). Chief investigators: Dr Doug Taupin; A/Prof Hany Elsaleh; Prof. Matthew Cook.
  • IHC and Local Recurrence in Breast Cancer (2013). Chief investigators: Dr Roopa Lakhanpal; Genevieve Bennet; Michael Brown.
  • Exercise in the management of symptoms from AI's in women with Breast Cancer (2013-2014). Chief investigator: Dr Angela Rezo.
  • Assessment of new Radiation Oncology Technology and Treatments (ANROTAT). Project chief investigators: Dr Lyn Austen; Janelle Hawkins; A/Prof Hany Elsaleh.
  • Palliative Rapid Access Clinic Project. Chief investigators: Dr Amy Shorthouse; Claire Stevens.
  • Breast Cancer Treatment Group (BCTG) Quality Assurance (2013-2014). Chief investigator: Dr Angela Rezo.
  • Discovery of potential synergistical interactions between novel chemotherapeutical agents and ionizing radiation (2013) - 2014). Chief investigators: Dr Alesia Ivashkevich; A/Prof Hany Elsaleh.
  • Investigation into mechanisms and modulation of toxicity of chemical radioprotectors (2013-2014). Chief investigators: Dr Alesia Ivashkevich; A/Prof Hany Elsaleh.
  • Novel mechanisms of normal tissue toxicity and repair (2013 - 2014). Chief investigators: Dr Alesia Ivashkevich; A/Prof Hany Elsaleh.

Recent Publications

A list of publications from the past 18 months:

  • O.A. Martin, R.L. Anderson, P.A. Russell, R.A. Cox, A. Ivashkevich, A. Swierczak, P.J. Doherty, D.H. Jacobs, J. Smith, S. Siva, P.E. Daly, D.L. Ball, R.F. Martin, M.P. MacManus. Mobilization of viable tumour cells into the circulation during radiation therapy. Int J Radiat Oncol Biol Phys 88 (2014) 395-403.
  • J.H. Chang, D. Lim Joon, B.T. Nguyen, C.Y. Hiew, S. Esler, D. Angus, M. Chao, M.Wada, G. Quong, V. Khoo, MRI scans significantly change target coverage decision in radical radiotherapy for prostate cancer. J Med Imaging Radiat Oncol 58 (2014) 237-243.
  • C.N. Sprung, A. Ivashkevich, H.B. Forrester, C.E. Redon, A. Georgakilas, O.A. Martin. Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects. Cancer Lett 14 (2013)00661-00667.
  • O.A. Martin, A Ivashkevich, S. Choo, L. Woodbine, P.A. Jeggo, R.F. Martin, P. Lobachevsky, Statistical analysis of kinetics, distribution and co-localisation of DNA repair foci in irradiated cells: cell cycle effect and implications for prediction of radiosensitivity. DNA Repair 12 (2013) 844-855.
  • H.B. Forrester, A. Ivashkevich, M.J. McKay, T. Leong, D.M. de Kretser, C.N. Sprung, Follistatin is induced by ionizing radiation and potentially predictive of radiosensitivity in radiation-induced fibrosis patient derived fibroblasts. PLoS One 8 (2013).
  • E.C. Behm, K.R. Beckmann, J.E. Dahlstrom, Y. Zhang, C. Cho, R. Stuart-Harris, P.Craft, A. Rezo, J.M. Buckingham, Surgical margins and risk of locoregional recurrence in invasive breast cancer: an analysis of 10 year data from the Breast Cancer Treatment Quality Assurance Project. Breast 22 (2013) 830-844.
  • M. Baird, P. Woon Ang,I. Clark, D. Bishop, M. Oshima, M.C. Cook, C. Hemmings, S. Takeishi, D. Worthley, A. Boussioutas, T.C. Wang, D. Taupin. The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner. Lab Invest 93 (2013) 112-122.
  • B.T. Nguyen, S. Deb, S. Fox, P.Hill, M. Collins, B.H. Chua. A prospective pathologic study to define the clinincal target volume for partial breast radiation therapy in women with early breast cancer. Int J Radiat Oncol Biol Phys 84 (1012) 1116-1122.
  • M.P. Myklebust, Z. Li, T.H. Tran, H. Rui, E.S. Knudsen, H. Elsaleh, O. Fluge, B. Vonen, H.E. Myrvold, S. Leh, K.M. Tveit, R.G. Pestell, O. Dahl, Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer 107 (2012) 1684-1691.
  • A. Ivashkevich, C.E. Redon, A.J. Nakamura, R.F. Martin, O.A. Martin. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 327
  • J.J. Farrell, K. Bae, J. Wong, C. Guha, A.P. Dicker, H. Elsaleh,. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 12 (2012) 395-403.

Contact Us:

Cancer central access number PH: 6174 8444